More and more studies seem to come out showing the effects of Xolair for the treatment of chronic idiopathic urticaria (CIU).
A recent study published in the Annals of Allergy Asthma and Immunology has shown this anti-IgE monoclonal antibody as highly effective. They had 68 patients involved in the study and they were given a 150 mg dose monthly. Seventy nine percent achieved remission after therapy and 18% achieved improvement. The most common interval was 1-3 months. Their conclusion was it was successful in severe patients and it induced a long lasting positive response with well tolerated side effects.
This is good news for many chronic hive patients. Xolair is currently under going FDA approval for hives and hopefully for many suffering patients, this can be a solution to their problems.